Skip to content
Medical Health Aged Care

RACGP welcomes government ban on genetic testing discrimination in life insurance

Royal Australian College of GPs < 1 mins read

The Royal Australian College of GPs (RACGP) welcomes the Federal Government announcing it will legislate to ban the use of genetic test results in life insurance underwriting. 

In a submission in response to a Federal Treasury consultation paper, the RACGP said the medical benefits of genetic testing risked being lost if Australians avoid testing because it could lead to them being denied insurance. 

RACGP President Dr Nicole Higgins said: “The RACGP welcomes the Government announcing that it will legislate a full ban on the use of adverse genetic testing results by life insurers. 

“Genetic testing has great potential to improve health outcomes for Australians, and people shouldn’t be afraid to get tested for fear that they’ll be denied insurance.  

“Genetic tests enable us to identify and manage risks for conditions that can be life threatening, such as familial breast cancer. Patients must be protected against genetic discrimination based on adverse results.” 

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992[email protected]

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care
  • 11/11/2025
  • 16:00
Uniting NSW.ACT

Results of Australia’s first injectable opioid treatment trial announced at 2025 APSAD conference

Media Release 11th November 2025 The results of Australia’s first injectable opioid treatment trial were revealed at the 2025 APSAD (The Australasian Professional Society on Alcohol and other Drugs) conference in Sydney today. Two presentations today outlined the initial findings of the trial – one by Dr Jake Rance, Centre for Social Research in Health at UNSW on ‘The ‘acceptability’ of supervised injectable opioid treatment: Staff and participant reflections from the Australian ‘Feasibility of Injectable Opioid Treatment’ (FOpIT) and the other by Dr Craig Rodgers on the initial outcomes of recruitment, retention and safety. The study is a partnership between…

  • Medical Health Aged Care
  • 11/11/2025
  • 12:26
Samsung Epis Holdings Co., Ltd.

Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms

INCHEON, Korea–BUSINESS WIRE– Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on…

  • Contains:
  • Government NSW, Medical Health Aged Care
  • 11/11/2025
  • 09:56
Go Gentle Australia & Dying with Dignity NSW

Opposition Mounts Against ‘Cruel’ NSW VAD Legislation

Key Facts: There will be a press conference to discuss the response to the Voluntary Assisted Dying Amendment (Residential Facilities) Bill 2025 When: Today…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.